In hepatocellular carcinoma, sorafenib and its derivative SC-59 both trigger autophagy through SHP-1-STAT3-Mcl-1-Beclin 1 pathway, with SC-59 showing greater efficacy in decreasing cancer cell viability and tumor growth (85). Here, BECN1 is linked to cancer.